Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 13/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12203063 | 0.82 | ALDH1A1 (0.52) | ALDH1A1LMNAKDM4EGLAL3MBTL1 | |
| SCHEMBL20197168 | 0.78 | PTGS1 (0.48) | PTPN11PTGS1PTGS2SLC22A12 | |
| SCHEMBL18924312 | 0.77 | SLC22A12 (0.41) | ALDH1A1LMNAKDM4EPTPN11GLA | |
| SCHEMBL22999518 | 0.74 | KDM4D (0.50) | ALDH1A1KDM4EPTGS1PTGS2SLC22A12 | |
| SCHEMBL22999832 | 0.74 | ACLY (0.54) | KDM4EL3MBTL1PTGS1PTGS2SLC22A12 | |
| SCHEMBL2054606 | 0.72 | ALDH1A1 (0.41) | ALDH1A1LMNAKDM4EL3MBTL1 | |
| SCHEMBL2556472 | 0.71 | TSHR (0.54) | ALDH1A1LMNAKDM4EPTGS1PTGS2 | |
| SCHEMBL27482604 | 0.71 | CA2 (0.50) | ALDH1A1LMNAGLAL3MBTL1AR | |
| SCHEMBL21889142 | 0.71 | ALDH1A1 (0.39) | ALDH1A1LMNAKDM4EL3MBTL1AR | |
| SCHEMBL22928260 | 0.71 | CA2 (0.58) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | ALDH1A1 779/4885LMNA 999/4885KDM4E 2233/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | ALDH1A1 779/4885LMNA 999/4885KDM4E 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.